Searchable abstracts of presentations at key conferences in endocrinology

ea0084ps3-14-128 | Thyroid Cancer CLINICAL 2 | ETA2022

Progrp as an additional screening marker in the diagnostic work up for medullary thyroid carcinoma

Schonebaum Leonoor , van Balkum Mathe , Visser W. Edward , van den Berg Sjoerd , Peeters Robin

Background: Medullary thyroid carcinoma (MTC) is a rare disease accounting for 1-3% of all thyroid carcinomas. Unfortunately, most patients present with metastasized disease: 70% with cervical lymph node metastasis and 5-10% with distant metastasis. Survival strongly correlates with stage of disease at diagnosis, illustrating the need for early diagnosis. Calcitonin is a well-established tumour marker for MTC, but its use in the screening phase is limited by a high rate of fal...

ea0056p1135 | Thyroid cancer | ECE2018

Improved prognostic value of the eighth edition of the AJCC/TNM staging system for differentiated thyroid cancer

van Velsen Evert , Stegenga Merel , van Kemenade Folkert , Kam Boen , van Ginhoven Tessa , Visser W Edward , Peeters Robin

Background: In January 2018, the 8th edition of the AJCC/TNM staging system for differentiated thyroid cancer (DTC) was introduced in clinical practice. Studies evaluating this 8th edition so far only comprised patients with papillary thyroid cancer (PTC) or made no distinction between PTC and follicular thyroid cancer (FTC). Therefore, we evaluated the prognostic value of the AJCC/TNM 8th edition in a European population with DTC, and subsequently distinguished PTC and FTC pa...